Jerome Jaubert
Overview
Explore the profile of Jerome Jaubert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
932
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thomas J, Ferme C, Noordijk E, Morschhauser F, Girinsky T, Gaillard I, et al.
Int J Radiat Oncol Biol Phys
. 2017 Dec;
100(5):1133-1145.
PMID: 29229324
Purpose: While patients with early-stage Hodgkin lymphoma (HL) have an excellent outcome with combined treatment, the radiation therapy (RT) dose and treatment with chemotherapy alone remain questionable. This noninferiority trial...
2.
Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, Marit G, et al.
J Clin Oncol
. 2012 May;
30(16):1949-52.
PMID: 22547600
Purpose: In multiple myeloma, many prognostic parameters have been proposed. However, all of these predict shorter survival. To identify patients with a longer life expectancy, we updated the data of...
3.
Flandrin-Gresta P, Callanan M, Nadal N, Jaubert J, Cornillon J, Guyotat D, et al.
Blood
. 2010 Dec;
116(23):5077-8.
PMID: 21127190
No abstract available.
4.
Moreau P, Attal M, Pegourie B, Planche L, Hulin C, Facon T, et al.
Blood
. 2010 Nov;
117(11):3041-4.
PMID: 21098740
In the 2005-01 trial, we have demonstrated that bortezomib-dexamethasone as induction therapy before autologous stem cell transplantation was superior to vincristine-adriamycin-dexamethasone. We conducted a post-hoc analysis to assess the prognostic...
5.
Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, et al.
Br J Haematol
. 2010 Aug;
151(2):159-66.
PMID: 20738307
Peripheral T-Cell lymphomas (PTCL) are relatively rare diseases but appear to be highly aggressive and display worse remission and survival rates than B-cell lymphomas. Despite unsatisfactory results with the cyclophosphamide,...
6.
Gyan E, Foussard C, Bertrand P, Michenet P, Le Gouill S, Berthou C, et al.
Blood
. 2008 Oct;
113(5):995-1001.
PMID: 18955565
Autologous stem cell transplantation (ASCT) as first-line therapy for follicular lymphoma (FL) remains controversial. The multicenter study randomized 172 patients with untreated FL for either immunochemotherapy or high-dose therapy (HDT)...
7.
Cazin B, Divine M, Lepretre S, Travade P, Tournilhac O, Delmer A, et al.
Br J Haematol
. 2008 Aug;
143(1):54-9.
PMID: 18710390
A multicentre single-arm study testing the efficacy and toxicity of the oral combination of fludarabine and cyclophosphamide (FC) over 5 d in 75 patients with untreated B cell-chronic lymphocytic leukaemia....
8.
Ferme C, Eghbali H, Meerwaldt J, Rieux C, Bosq J, Berger F, et al.
N Engl J Med
. 2007 Nov;
357(19):1916-27.
PMID: 17989384
Background: Treatment of early-stage Hodgkin's disease is usually tailored in line with prognostic factors that allow for reductions in the amount of chemotherapy and extent of radiotherapy required for a...
9.
Facon T, Mary J, Hulin C, Benboubker L, Attal M, Pegourie B, et al.
Lancet
. 2007 Oct;
370(9594):1209-18.
PMID: 17920916
Background: In multiple myeloma, combination chemotherapy with melphalan plus prednisone is still regarded as the standard of care in elderly patients. We assessed whether the addition of thalidomide to this...
10.
Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, et al.
N Engl J Med
. 2007 Sep;
357(11):1083-93.
PMID: 17855669
Background: High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation has been reported to provide higher response rates and better overall survival than standard chemotherapy in immunoglobulin-light-chain (AL) amyloidosis, but these...